Pexelizumab: Updated Phase III data

Alexion Pharmaceuticals Inc. (ALXN), Cheshire, Conn.
Procter & Gamble Co. (PG), Cincinnati, Ohio
Product: Pexelizumab (5G1.1-SC)
Business: Cardiovascular
Molecular target:

Read the full 216 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE